Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a ...

Dopamine maintains hope and motivation for life. Inflammation-associated compounds disrupt dopamine release, causing apathy.

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis — a primary driver of cardiovascular death ...

Researchers have uncovered new insights into the mechanisms behind severe schistosomiasis, focusing on how immune responses ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis — a primary driver of cardiovascular death worldwide — in large mammals, a study suggests.

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of ...

接着，研究人员探究了棕榈酰化是如何促进炎症小体形成的。通过活细胞显微镜观察，他们发现，受到 NLRP3 激活剂刺激后，NLRP3 会迅速在细胞质中形成具有动态、液体样行为的斑点，这和液 - 液相分离（LLPS）的特征相符。而且这个过程完全依赖于棕榈酰化，没有棕榈酰化的 NLRP3 无法形成斑点，也不能支持炎症小体激活。

Neushen Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, cardiovascular disorders, neurodegeneration and chronic obstructive ...

The IL-1 family, including IL-1β and IL-18, further exacerbates tissue damage by activating the NLRP3 inflammasome, a mechanism implicated in SLE2,3. These cytokines not only drive local inflammation ...

SYMPHONY 2 (HTD1801 as an add-on therapy to Metformin): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.2%) was superior to placebo. Further, those with more severe disease had a ...

NLRP3 inflammasome inhibitors are described in a Zomagen Biosciences Ltd. patent and are reported to be useful for the treatment of autoimmune, cardiovascular, inflammatory, liver, lung, metabolic and ...